Effects of estrogen on cell proliferation and leukotriene formation in transformed mouse Leydig cells cultured under serum-free conditions.
B-1 F cells from mouse Leydig cell tumor (T 124958-R) were maintained in serum-free culture. Estrogen enhanced the growth of the cells, and this growth was suppressed by antiestrogens such as 4-hydroxytamoxifen or TAT, a newly developed antiestrogen. Since the growth of B-1 F cells was recently found to be inhibited by the metabolites of arachidonic acid, we examined the relationship between this metabolism and the enhancement of cell growth by estrogen. Among the modulators affecting the metabolism of arachidonic acid, 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoqu inone, an inhibitor of 5-lipoxygenase, reproducibly stimulated the growth of the cells, whereas the cyclooxygenase inhibitor indomethacin had only the marginal growth-stimulatory effects. Phorbol ester had no growth-modulating effect. 17 beta-Estradiol and 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoqu inone had some additive effects especially in terms of restoration of antiestrogen-induced inhibition. Moreover, the inhibition of DNA synthesis elicited by the addition of arachidonic acid in concentrations of 0.05 to 0.5 micrograms/ml was partly blocked by estrogen. Analyses of extracts of media and cells by high-pressure liquid chromatography and radioimmunoassay showed that 17 beta-estradiol inhibited the synthesis of leukotrienes B4, C4, D4, and E4 and this inhibition could be restored by antiestrogen. These results suggest that the enhancement of B-1 F cell growth by estrogen is at least partly mediated through its ability to inhibit leukotriene synthesis.
Nishizawa
Y
Y
Third Department of Internal Medicine, Osaka University Hospital, Japan.
Nishii
K
K
Nishizawa
Y
Y
Koga
M
M
Kishimoto
S
S
Matsumoto
K
K
Sato
B
B
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D003470:Culture Media; D004965:Estrogen Antagonists / Q000494:pharmacology*; D004967:Estrogens / Q000494:pharmacology*; D007984:Leydig Cell Tumor / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology*; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000473:pathology
D001095:Arachidonic Acids; D003470:Culture Media; D004965:Estrogen Antagonists; D004967:Estrogens; D013629:Tamoxifen; C064590:2-(4-(1-(4-hydroxyphenyl)-2-(4-isopropylphenyl)-1-butenyl)phenoxy)-N,N-dimethylethylamine; C016601:afimoxifene